Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamous cell carcinoma of the lung.

          Related collections

          Author and article information

          Journal
          Lancet Oncol.
          The Lancet. Oncology
          1474-5488
          1470-2045
          Aug 2015
          : 16
          : 8
          Affiliations
          [1 ] Gustave Roussy Cancer Campus and University Paris-Sud, Paris, France. Electronic address: Jean-Charles.Soria@gustaveroussy.fr.
          [2 ] Medical Oncology Department, Vall d' Hebron University Hospital, Vall d' Hebron Institute of Oncology, Barcelona, Spain.
          [3 ] Hospital Carlos Haya, Malaga, Spain.
          [4 ] Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
          [5 ] Athens School of Medicine, Athens, Greece.
          [6 ] Chungbuk National University College of Medicine, Cheongju, South Korea.
          [7 ] Ege University Faculty of Medicine, Izmir, Turkey.
          [8 ] Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
          [9 ] First Hospital Affiliated to Jilin University, Jilin, China.
          [10 ] Hospital Lozano Blesa, Zaragoza, Spain.
          [11 ] Izmir Chest Diseases Research Hospital, Izmir, Turkey.
          [12 ] Istituto Nazionale Tumori "Fondazione G Pascale"-IRCCS, Naples, Italy.
          [13 ] Department of Medicine, Ulsan University Hospital, Ulsan, South Korea.
          [14 ] University Hospital, Bologna, Italy.
          [15 ] Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
          [16 ] Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
          [17 ] Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada.
          Article
          S1470-2045(15)00006-6
          10.1016/S1470-2045(15)00006-6
          26156651
          Copyright © 2015 Elsevier Ltd. All rights reserved.

          Comments

          Comment on this article